Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eteplirsen Approval Reflected FDA's Conflict On Accelerated Approval – Former Sarepta CEO

Executive Summary

There is anxiety within the US agency over use of the pathway amid the prospect for confirmatory trials to fail, former CEO Garabedian says at FDA/CMS Summit.


Related Content

Drug Review Profiles: Behind The Scenes At US FDA
Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Exondys 51 Reviewers
Exondys 51 Clinical Development Timeline
Exondys 51’s Development: Was Placebo-Controlled Trial Possible?
No More Sarepta-Like Development, FDA Officials Say
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Hoping To Smooth Relations With FDA, Sarepta Moves On From CEO Garabedian


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts